Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chimeric antigen receptor comprising C3aR intracellular structural domain, lentiviral vector, expression cell and drug

A chimeric antigen receptor, intracellular domain technology, applied in receptors/cell surface antigens/cell surface determinants, viruses/phages, retroRNA viruses, etc. How does the chimeric antigen receptor work, etc., to improve the killing efficiency in vitro, improve the killing effect, and eliminate the effects of immunosuppression

Active Publication Date: 2018-04-13
GUANGDONG GENERAL HOSPITAL
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The third generation CAR-T has been used in clinical trials of mantle cell lymphoma (MCL) and follicular non-Hodgkin lymphoma (NHL), but it has not shown better clinical results than the second generation
Combining C3aR with other co-stimulatory molecules is used for the construction of chimeric antigen receptors, and it is impossible to predict the effect of the constructed chimeric antigen receptors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor comprising C3aR intracellular structural domain, lentiviral vector, expression cell and drug
  • Chimeric antigen receptor comprising C3aR intracellular structural domain, lentiviral vector, expression cell and drug
  • Chimeric antigen receptor comprising C3aR intracellular structural domain, lentiviral vector, expression cell and drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Preparation of plasmid containing anti-CD19ScFv-4-1BB-CD3ζ-C3aR (CAR19C3aR)

[0032] Prepare the plasmid of the present invention carrying the chimeric antigen receptor gene containing the intracellular domain of C3aR as follows:

[0033] (1) The plasmid pUC57-CAR19 containing anti-CD19ScFv-4-1BB-CD3ζ (CAR19) was obtained by means of gene synthesis and molecular cloning, including anti-CD19 monoclonal antibody ScFv, CD28 transmembrane region and 4-1BB, CD3ζ intracellular region , namely CD19ScFv-4-1BB-CD3ζ.

[0034] (2) The resulting pUC57-CAR19 plasmid was digested with endonucleases Pmel and Sepl to obtain the CAR19 gene, and then the CAR19 gene was connected to the lentiviral vector pWPXLd-GFP to construct pWPXLd-CAR19-GFP.

[0035] (3) Digest the obtained pWPXLd-CAR19-GFP plasmid with endonucleases NotI and SpeI to obtain the intracellular fragment 4-1BB-CD3ζ of the CAR19 gene.

[0036] (4) Using the cDNA of 4-1BB-CD3ζ tandem C3aR intracellular signaling...

Embodiment 2

[0039] Lentiviral packaging of embodiment 2CAR plasmid

[0040] Three lentiviruses expressing GFP (blank control), CAR19-GFP (control), and CAR19C3aR-GFP were obtained by using the CAR plasmid of the present invention prepared in Example 1 and related control plasmids through lentiviral packaging. In Examples 2 and 3, the CAR-containing plasmid is collectively described as pWPXLd-CAR-GFP plasmid, and the CAR-overexpressing lentivirus is collectively described as CAR lentivirus.

[0041] Specific steps are as follows:

[0042] (1) Cultivate 293T cells in a 10cm culture dish, the culture medium is: DMEM high glucose medium + 10% FBS (fetal bovine serum) + 1% double antibody (100 × penicillin-streptomycin mixed solution);

[0043] (2) When the 293T cell density in the 150mm culture dish reaches 80-90%, replace the medium: DMEM high glucose medium + 1% FBS + 1% double antibody;

[0044] (3) After replacing the medium and culturing for 2-6 hours, the two plasmids pWPXLd-CAR-GFP (...

Embodiment 3

[0052] Example 3 Using packaged CAR virus to infect human T cells

[0053] (1) Separation and purification of T cells: the mononuclear cells in the blood are separated by the Ficoll density gradient method, and the red blood cells are removed by lysing with the red blood cell lysate, and then the T cells are sorted by MACS Pan-T magnetic beads;

[0054] (2) The sorted T cells were diluted with culture medium (AIM-V medium+5% FBS+penicillin 100U / ml+streptomycin 0.1mg / ml) to a cell concentration of 2.5×10 6 pcs / ml for use;

[0055] (3) Stimulate T cells by magnetic beads coated with CD2, CD3, and CD28 antibodies (product source: Miltenyi, Germany), that is, the coated magnetic beads and T cells are mixed at a ratio of 1:2, and the final density of T cells should be 5 ×10 6 A / ml / cm2. After mixing, place them in a 37°C, 5% CO2 incubator to incubate and stimulate for 48 hours.

[0056] (4) Lentiviral transfection of T cells: remove the magnetic beads in the activated T cell-magne...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a chimeric antigen receptor comprising a C3aR intracellular structural domain, a lentiviral vector, an expression cell and a drug. The chimeric antigen receptor comprising the C3aR intracellular structural domain comprises an extracellular structural domain capable of being combined with an antigen, a transmembrane structural domain and at least one intracellular structuraldomain. The intracellular structural domain is selected from the C3aR intracellular structural domain or the intracellular structural domain in a signal transfer region connected to the C3aR intracellular structural domain in series. The chimeric antigen receptor can improve the T17 cell subgroup, eliminate the action of adjusting the immune inhibition of a T cell, can remarkably improve the in vitro killing efficiency of a tumor target cell and remarkably improve the killing effect of a second generation CAR T cell on tumors, thereby providing a novel concept and selection in the field of CAR-T cell treatment.

Description

technical field [0001] The invention belongs to the technical field of tumor cell immunotherapy, and specifically relates to a chimeric antigen receptor comprising a C3aR intracellular domain, and also relates to a nucleic acid and application of the chimeric antigen receptor encoding a C3aR intracellular domain. Background technique [0002] Chimeric Antigen Receptors (CAR, Chimeric Antigen Receptors) T cells are a milestone event that is expected to cure tumors. CAR-T technology uses genetic modification technology to combine a single chain fragment variable (scFv) that recognizes tumor antigens with cells. The internal activation motif recombinant gene is transfected to T lymphocytes to achieve better tumor recognition and killing effects. CAR-T molecules usually include an extracellular hinge region, a transmembrane region, and an intracellular signal region. Among them, the extracellular hinge region is formed by connecting the heavy chain and light chain variable regi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/867C12N5/10A61K35/17A61P35/00A61P35/02
CPCC12N15/86C07K14/7051C07K2319/33C12N2740/15043A61K2239/31A61K39/4611A61K39/4631A61K2239/48A61K2239/38A61K39/464412
Inventor 杜欣翁建宇赖沛龙陈晓梅
Owner GUANGDONG GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com